. 2022 Mar 5;42(4):771–782. doi: 10.1007/s10875-022-01233-5

Table 1.

Immunological features of the two patients

Population/Parameter	II.2	Reference values	II.3	Reference values
White blood cells (/µl)	4,900	4,800 – 13,080	16,500	5,400 – 13,800
Granulocytes (%)	61	50 – 80	54.2	25 – 68
Lymphocytes (%)	28	25 – 50	38.8	28 – 59
CD19⁺ (/µl)	277	390 – 1,400	1,061	390 – 1,400
CD27⁻/ CD19⁺ (%)	90.1	76.3—89.2	80.2	76.3—89.2
IgD⁺IgM⁺CD24⁺CD38⁺CD27⁻/ CD19⁺ (%)	41.1	50.3—67.2	30.3	50.3—67.2
IgD⁺IgM⁺CD24⁺CD38⁻CD27⁻/ CD19⁺ (%)	8.4	2.8—10.6	17	2.8—10.6
IgD⁺IgM⁺CD24⁺⁺CD38⁺⁺CD27⁻/ CD19⁺ (%)	25.4	6.5—17.1	17.4	6.5—17.1
CD27⁺/ CD19⁺ (%)	8.5	9.1—21.4	17.3	9.1—21.4
IgD⁺IgM⁺CD27⁺/ CD19⁺ (%)	6.5	3.7—9.4	14.9	3.7—9.4
IgD⁻IgM⁺ CD27⁺/ CD19 ⁺ (%)	1	0.1—0.7	0.7	0.1—0.7
IgD⁺IgM⁻CD27⁺/ CD19⁺ (%)	0.7	0.9—2.6	1.6	0.9—2.6
IgD⁻IgM⁻CD27⁺/ CD19⁺ (%)	0.3	2—8.6	0.1	2—8.6
IgD⁻IgM⁻CD27⁻/ CD19⁺ (%)	0.6	1.7—8.4	0.3	1.7—8.4
CD27⁺ ⁺CD38⁺ ⁺/ CD19⁺ (%)	0.1	0.1—0.4	0.04	0.1—0.4
CD21⁻CD38⁻/ CD19⁺ (%)	1.7	1.8—6.5	0.4	1.8—6.5
CD3⁻CD56⁺ (/µl)	120	130 – 720	503	130 – 720
CD3⁺CD4⁺ (/µl)	556	700 – 2,200	1,751	700 – 2,200
CD31⁺CD45RA⁺/ CD4⁺ (%)	44.4	53 – 74	55.1	52 – 67
CD27⁺CD45RA⁺/ CD4⁺ (%)	55.3	65 – 84	75.1	72 – 84
CD27⁺CD45RA⁻/ CD4⁺ (%)	35.2	14 – 33	21.8	15 – 26
CD27⁻CD45RA⁻/ CD4⁺ (%)	8.7	0.4 – 3.4	3.0	0.5 – 2.2
CD27⁻CD45RA⁺/ CD4⁺ (%)	0.8	0.1 – 1.1	0.1	0 – 0.9
CD3⁺CD8⁺ (/µl)	209	490 – 1,300	653	490 – 1,300
CD27⁺CD45RA⁺/ CD8⁺ (%)	57.1	55 – 91	60.6	57 – 91
CD27⁺CD45RA⁻/ CD8⁺ (%)	26.8	6 – 23	23.7	6 – 22
CD27⁻CD45RA⁻/ CD8⁺ (%)	7.5	0.4 – 13	6.4	0 – 7
CD27⁻CD45RA⁺/ CD8⁺ (%)	8.6	0.8 – 22	9.2	0.6 – 16
IgM (g/l)	7.2	0.24 – 2.1	6.3	0.52 – 1.9
IgA (g/l)	< 0.1	0.27 – 1.95	< 0.05	0.3 – 1.9
IgG (g/l)	< 0.3	5.04 – 14.64	< 0.4	5.4 – 13.4
Anti-Tetanus IgG (U/ml)	< 0.01	> 0.1	n.a	> 0.1
Anti-PcP IgG (mg/l)	< 3.3	0.8—262	n.a	0.8—262

Reference values are age-matched from the local laboratory and [23, 24] (n.a., not assessed)